Podcast

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

Author(s):

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Welcome to OncLive On Air. I'm your host today, Jason Harris. OncLive On Air is a podcast from OncLive, which provides oncology professional with the resources and information they need to provide the best patient care.

In both digital and print formats, OncLive covers every angle of oncology practice, from new technologies to treatment advances to important regulatory decisions.

In today's episode, Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab (Herceptin) as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Related Videos
Ruth M. O’Regan, MD
Peter Forsyth, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health